Curocell큐로셀
372320 · KOSDAQ · ₩372320 · 큐로셀
- Market cap
- ₩372B
- Enterprise value
- ₩413B
- P/E
- —
- P/B
- 5.1×
- Dividend yield
- 0.0%
- ROE
- −74.6%
- Net margin
- —
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−63.0% from the high
₩20,650Today: ₩23,100 – ₩24,900₩66,000
Returns
- 1W+1.5%
- 1M+15.1%
- 3M+7.5%
- 6M−62.1%
- YTD−45.7%
- 1Y−38.1%
- Volume today
- 29,112
- 0.7× the 20-day average
- Traded today
- ₩711M
- Listed shares
- 15,227,152
- EPS (12 months)
- −₩3,552
- Earnings yield −14.6%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 42 of 100 (50 is a normal day for this stock).
- MomentumStrong16.7% over the last month; the price is above its 20-day average.
- News impactLow2 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Curocell stock overview
Curocell (큐로셀, KRX: 372320) is listed on KOSDAQ, in the Biotech & Pharma sector. This Korean company is a cell and gene therapy developer focused on improving the cancer-fighting effect of CAR-T therapies, founded in 2016. Its shares closed at ₩24,400 on Oct 27, 2026, up 4.72% on the day, giving it a market value of ₩372B.
Key facts
- Market cap
- ₩372B
- Sector
- Biotech & Pharma
- Latest price change
- +4.72%
- As of
- Oct 27, 2026
- Main business
- This Korean company is a cell and gene therapy developer focused on improving the cancer-fighting effect of CAR-T therapies, founded in 2016.
Quick answers about Curocell
- What does Curocell do?
- This Korean company is a cell and gene therapy developer focused on improving the cancer-fighting effect of CAR-T therapies, founded in 2016. Its lead product, CRC01 (anbalcabtagene autoleucel, brand name Rimcato), is a CD19 CAR-T therapy built on its proprietary OVIS CAR-T technology, which also suppresses the immune checkpoint receptors PD-1 and TIGIT. The company is seeking approval in Korea, plans to manufacture and sell domestically through its own commercial GMP facility in Daejeon, and pursues overseas markets through technology transfer or partnering.
- What is the market cap of Curocell?
- The market capitalisation of Curocell was ₩372B at the close on Oct 27, 2026.
- Who are the largest shareholders of Curocell?
- According to the latest official filings, the largest reported holders are Kim Geon-su (29.34%, as of Jul 23, 2026); Kim Chan-hyeok (9.12%, as of Jul 24, 2026); Mirae Asset Celltrion New Growth Investment Partnership No. 1 (5.76%, as of May 7, 2026).
- When is the next earnings report from Curocell?
- Korean companies rarely announce results dates in advance. Based on when Curocell filed the same report in past years, its next 3q results is expected around Nov 13, 2026.
- Does the National Pension Service own Curocell?
- Yes. The National Pension Service held 0.46% of Curocell shares as of Dec 31, 2025.
Company profile
This Korean company is a cell and gene therapy developer focused on improving the cancer-fighting effect of CAR-T therapies, founded in 2016. Its lead product, CRC01 (anbalcabtagene autoleucel, brand name Rimcato), is a CD19 CAR-T therapy built on its proprietary OVIS CAR-T technology, which also suppresses the immune checkpoint receptors PD-1 and TIGIT. The company is seeking approval in Korea, plans to manufacture and sell domestically through its own commercial GMP facility in Daejeon, and pursues overseas markets through technology transfer or partnering.
Written by AI from the company's latest annual report.
- Korean name
- 큐로셀
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 김건수
- Founded
- Dec 2016
- Listed
- Nov 2023
- Listed shares
- 15,227,152
- Fiscal year ends
- Month 12
- Website
- curocellbtx.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Major management matter relevant to investorsOct 27, 2026
- Insider shareholding reportOct 21, 2026
- Insider shareholding reportSep 9, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Insider shareholding reportJul 24, 2026
Titles in Korean until English translations are added.
Also known as: Curocell / 큐로셀 / 372320 / KRX:372320
Source: KRX statistical information